92 related articles for article (PubMed ID: 2295063)
1. Efficacy, toxicity, pharmacokinetics, and in vitro metabolism of the enantiomers of ifosfamide in mice.
Masurel D; Houghton PJ; Young CL; Wainer IW
Cancer Res; 1990 Jan; 50(2):252-5. PubMed ID: 2295063
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and toxicity of ifosfamide stereoisomers in an in vivo rat mammary carcinoma model.
Wainer IW; Granvil CP; Wang T; Batist G
Cancer Res; 1994 Aug; 54(16):4393-7. PubMed ID: 8044787
[TBL] [Abstract][Full Text] [Related]
3. Phenytoin-induced alteration in the N-dechloroethylation of ifosfamide stereoisomers.
Ducharme MP; Bernstein ML; Granvil CP; Gehrcke B; Wainer IW
Cancer Chemother Pharmacol; 1997; 40(6):531-3. PubMed ID: 9332469
[TBL] [Abstract][Full Text] [Related]
4. Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients.
Granvil CP; Ducharme J; Leyland-Jones B; Trudeau M; Wainer IW
Cancer Chemother Pharmacol; 1996; 37(5):451-6. PubMed ID: 8599868
[TBL] [Abstract][Full Text] [Related]
5. Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide.
Struck RF; Dykes DJ; Corbett TH; Suling WJ; Trader MW
Br J Cancer; 1983 Jan; 47(1):15-26. PubMed ID: 6821629
[TBL] [Abstract][Full Text] [Related]
6. Reciprocal cross-resistance in human rhabdomyosarcomas selected in vivo for primary resistance to vincristine and L-phenylalanine mustard.
Horton JK; Houghton PJ; Houghton JA
Cancer Res; 1987 Dec; 47(23):6288-93. PubMed ID: 2890432
[TBL] [Abstract][Full Text] [Related]
7. [Metabolism of enantiomers of the cytostatic ifosfamide].
Blaschke G; Widey W
Arzneimittelforschung; 1989 Feb; 39(2):223-6. PubMed ID: 2730691
[TBL] [Abstract][Full Text] [Related]
8. The determination of (-)-(S)- and (+)-(R)-ifosfamide in plasma using enantioselective gas chromatography: a validated assay for pharmacokinetic and clinical studies.
Young CL; Frank H; Stewart CR; Wainer IW
Chirality; 1989; 1(3):235-8. PubMed ID: 2642052
[TBL] [Abstract][Full Text] [Related]
9. Enantioselective metabolism of ifosfamide by the kidney.
Aleksa K; Ito S; Koren G
Chirality; 2006 Jun; 18(6):398-405. PubMed ID: 16575879
[TBL] [Abstract][Full Text] [Related]
10. Enantioselective cytotoxic activity of bromine-substituted analogues of ifosfamide. A microsomal implication.
Hładoń B; Sloderbach A; Laskowska H
Pol J Pharmacol; 1997; 49(2-3):127-36. PubMed ID: 9437759
[TBL] [Abstract][Full Text] [Related]
11. Determination of the enantiomers of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in plasma and urine using enantioselective gas chromatography with mass spectrometric detection.
Granville CP; Gehrcke B; König WA; Wainer IW
J Chromatogr; 1993 Dec; 622(1):21-31. PubMed ID: 8120109
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological evaluation of ifosfamide and its enantiomers in laboratory animals.
Kleinrok Z; Chmielewska B; Czuczwar JS; Rajtar G; Sawiniec Z; Jarzabek G
Arch Immunol Ther Exp (Warsz); 1986; 34(3):293-304. PubMed ID: 3592933
[TBL] [Abstract][Full Text] [Related]
13. Chemical stability and fate of the cytostatic drug ifosfamide and its N-dechloroethylated metabolites in acidic aqueous solutions.
Gilard V; Martino R; Malet-Martino M; Niemeyer U; Pohl J
J Med Chem; 1999 Jul; 42(14):2542-60. PubMed ID: 10411475
[TBL] [Abstract][Full Text] [Related]
14. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450.
Chen CS; Jounaidi Y; Waxman DJ
Drug Metab Dispos; 2005 Sep; 33(9):1261-7. PubMed ID: 15919850
[TBL] [Abstract][Full Text] [Related]
15. The N-dechloroethylation of ifosfamide: using stereochemistry to obtain an accurate picture of a clinically relevant metabolic pathway.
Wainer IW; Ducharme J; Granvil CP
Cancer Chemother Pharmacol; 1996; 37(4):332-6. PubMed ID: 8548878
[TBL] [Abstract][Full Text] [Related]
16. Comparative studies on biological activity of /+/R and /-/S enantiomers of cyclophosphamide and ifosfamide. I. Antitumour effect of cyclophosphamide and ifosfamide enantiomers.
Paprocka M; Kuśnierczyk H; Budzyński W; Rak J; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1986; 34(3):275-84. PubMed ID: 3592931
[TBL] [Abstract][Full Text] [Related]
17. Effects of temperature on the therapeutic efficacy and pharmacokinetics of ifosfamide.
Wiedemann GJ; Siemens HJ; Mentzel M; Biersack A; Wössmann W; Knocks D; Weiss C; Wagner T
Cancer Res; 1993 Sep; 53(18):4268-72. PubMed ID: 8364922
[TBL] [Abstract][Full Text] [Related]
18. Influence of substrate configuration on chlorpheniramine N-demethylation by hepatic microsomes from rats, rabbits, and mice.
Thompson JA; Shioshita GW
Drug Metab Dispos; 1981; 9(1):5-9. PubMed ID: 6111432
[TBL] [Abstract][Full Text] [Related]
19. New insights into the pharmacokinetics and metabolism of (R,S)-ifosfamide in cancer patients using a population pharmacokinetic-metabolism model.
Di Marco MP; Wainer IW; Granvil CL; Batist G; Ducharme MP
Pharm Res; 2000 Jun; 17(6):645-52. PubMed ID: 10955835
[TBL] [Abstract][Full Text] [Related]
20. Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.
Silies H; Blaschke G; Hohenlöchter B; Rossi R; Jürgens H; Boos J
Int J Clin Pharmacol Ther; 1998 May; 36(5):246-52. PubMed ID: 9629987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
